Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR.


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
01 02 2022
Historique:
received: 31 07 2021
accepted: 20 09 2021
pubmed: 21 12 2021
medline: 14 4 2022
entrez: 20 12 2021
Statut: ppublish

Résumé

DICER1 syndrome is an autosomal dominant inherited syndrome predisposing to various benign and malignant tumors, mainly occurring in children and young adults, requiring broad surveillance starting at birth with repeated irradiating imaging exams and sedations for young patients. It is caused by monoallelic germline pathogenic variants in the DICER1 gene. More than 90% of tumors bear an additional somatic DICER1 missense hotspot mutation, as a second hit, involving 1 of 6 codons clustered in exons 24 and 25. We designed and in vitro validated a drop-off droplet digital PCR (ddPCR) system to scan all DICER1 hotspot codons, allowing for a liquid biopsy test, an alternative to sedation and radiation exposure. Three drop-off ddPCR assays were designed, with 2 TaqMan probes per assay, 1 complementary to the wild-type sequence of the region containing hotspots and another 1 used as a reference. Eight tumor-derived DNAs and 5 synthetic oligonucleotides bearing DICER1 hotspot mutations were tested. All tested mutations were detected, with a limit of detection ranging from 0.07% to 0.31% for codons p. E1705, p. D1709, and p. D1713 in exon 24 and from 0.06% to 0.15% for codons p. G1809, p. D1810, and p. E1813 in exon 25. The high sensitivity of this method is compatible with its use for plasma circulating tumor DNA (ctDNA) analysis for early tumor detection in DICER1 syndrome patients. It may reduce the need for radiation exposure and sedation in surveillance protocols and may also improve patient prognosis. Clinical trials are needed to evaluate ctDNA analysis in these patients.

Sections du résumé

BACKGROUND
DICER1 syndrome is an autosomal dominant inherited syndrome predisposing to various benign and malignant tumors, mainly occurring in children and young adults, requiring broad surveillance starting at birth with repeated irradiating imaging exams and sedations for young patients. It is caused by monoallelic germline pathogenic variants in the DICER1 gene. More than 90% of tumors bear an additional somatic DICER1 missense hotspot mutation, as a second hit, involving 1 of 6 codons clustered in exons 24 and 25. We designed and in vitro validated a drop-off droplet digital PCR (ddPCR) system to scan all DICER1 hotspot codons, allowing for a liquid biopsy test, an alternative to sedation and radiation exposure.
METHODS
Three drop-off ddPCR assays were designed, with 2 TaqMan probes per assay, 1 complementary to the wild-type sequence of the region containing hotspots and another 1 used as a reference. Eight tumor-derived DNAs and 5 synthetic oligonucleotides bearing DICER1 hotspot mutations were tested.
RESULTS
All tested mutations were detected, with a limit of detection ranging from 0.07% to 0.31% for codons p. E1705, p. D1709, and p. D1713 in exon 24 and from 0.06% to 0.15% for codons p. G1809, p. D1810, and p. E1813 in exon 25.
CONCLUSIONS
The high sensitivity of this method is compatible with its use for plasma circulating tumor DNA (ctDNA) analysis for early tumor detection in DICER1 syndrome patients. It may reduce the need for radiation exposure and sedation in surveillance protocols and may also improve patient prognosis. Clinical trials are needed to evaluate ctDNA analysis in these patients.

Identifiants

pubmed: 34928333
pii: 6470609
doi: 10.1093/clinchem/hvab248
doi:

Substances chimiques

Circulating Tumor DNA 0
Codon 0
DICER1 protein, human EC 3.1.26.3
Ribonuclease III EC 3.1.26.3
DEAD-box RNA Helicases EC 3.6.4.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

322-331

Subventions

Organisme : The Comité Île-de-France de la Ligue contre le Cancer

Informations de copyright

© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Roseline Vibert (R)

Service de Génétique, Institut Curie, Paris, France.
Université PSL, Paris, France.

Marion Gauthier-Villars (M)

Service de Génétique, Institut Curie, Paris, France.
Université PSL, Paris, France.

Christelle Carrière (C)

Service de Génétique, Institut Curie, Paris, France.
Université PSL, Paris, France.

Catherine Dubois d'Enghien (C)

Service de Génétique, Institut Curie, Paris, France.
Université PSL, Paris, France.

Joanna Cyrta (J)

Université PSL, Paris, France.
Service d'Anatomo-Pathologie, Institut Curie, Paris, France.

Anne Vincent-Salomon (A)

Université PSL, Paris, France.
Service d'Anatomo-Pathologie, Institut Curie, Paris, France.

Dominique Stoppa-Lyonnet (D)

Service de Génétique, Institut Curie, Paris, France.
Université de Paris, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma Paris, France.

Ivan Bièche (I)

Service de Génétique, Institut Curie, Paris, France.
Université de Paris, Paris, France.

Emmanuelle Jeannot (E)

Service de Génétique, Institut Curie, Paris, France.
Université PSL, Paris, France.
Service d'Anatomo-Pathologie, Institut Curie, Paris, France.

Lisa Golmard (L)

Service de Génétique, Institut Curie, Paris, France.
Université PSL, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH